SAGB.DIA.14.07.0290r, SAGB.DIA.14.08.0339h

Call our Diabetes Care Line on 08000 352525

GLP-1 Receptor Agonist

GLP-1 Receptor Agonist

Glucagon-like-peptide-1 (GLP-1) receptor agonists are used for the treatment of type 2 diabetes. These incretin-based therapies are a group of injectable medicines, but they are now used routinely for the treatment of type 2 diabetes.

Lyxumia® (lixisenatide)

Lyxumia is a once-daily GLP-1 receptor agonist. It is administered via an easy-to-use fixed dose pen device.

To help your patients to administer their Lyxumia safely in an informed manner, Sanofi have developed a range of patient support materials.

  • View the Lyxumia prescribing information here
  • View the Lyxumia summary of product characteristics here

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to the Sanofi drug safety department on 08000 352525.


You are now leaving the Diabetes Matters website

You are leaving the website. This link will take you to a website to which our Privacy Policy does not apply.

Sanofi UK has no control over the contents of these sites or resources, and accepts no responsibility for them or for any loss or damage that may arise from your use of them.

This section is for healthcare professionals only

Please note:

You are about to visit a section of the website that has been developed for healthcare professionals only. By accepting the confirmation below you confirm that you are a UK healthcare professional.

If you are not a healthcare professional, please return to the main Diabetes Matters website.